#China #Shanghai #RoosterBio #MineBio #MSC Bioprocessing

RoosterBio and MineBio Collaborate to Enhance MSC Bioprocessing in China

In a strategic move aimed at improving regenerative medicine in China, RoosterBio, Inc., a prominent supplier of human mesenchymal stem/stromal cells (hMSCs), has formed a partnership with MineBio Life Sciences Limited. This collaboration is set to expand access to highly engineered media and advanced therapy solutions for mesenchymal stem cells (MSCs) and exosomes within the rapidly growing Chinese biopharmaceutical landscape.

Headquartered in Frederick, Maryland, RoosterBio specializes in research-grade MSCs and media used in advanced therapy manufacturing. Recognizing the swift advancement in MSC and exosome clinical research in China, the partnership with MineBio—an established distributor in the region—creates a pathway for enhanced access to these critical resources.

Exciting Developments in Biopharmaceuticals

Tim Kelly, CEO of RoosterBio, applauded the collaboration, noting that China has become a hub for MSC and exosome clinical research, engaging in one of the highest concentrations of active clinical trials in the world. This partnership is expected to address the needs of developers aiming to translate lab innovations into therapeutic applications for patients effectively.

MineBio is poised to distribute RoosterBio's full suite of research-grade products and cGMP-grade CliniControl™ products throughout China, having already secured the necessary import regulations that allow immediate order fulfillment. This is crucial as it guarantees that developers can access the needed materials without delays, ultimately assisting them in accelerating their clinical trial timelines.

Products That Drive Innovation

The CliniControl™ product line includes essential resources for MSC expansion, exosome collection, and bioreactor feeds, supporting the complete product development continuum from early-stage research to cGMP manufacturing. This comprehensive offering is backed by regulatory documentation, including FDA Type II Master Files, ensuring that developers have the necessary support for trials in various jurisdictions.

MineBio's established relationships and expertise within the regenerative medicine sector further equip them to deliver RoosterBio's products effectively across the different stages of therapy development. This nuance is particularly important, considering the rapid evolution within China's regenerative medicine landscape.

Meeting Industry Demands

Amy Zuo, General Manager of MineBio, emphasized the vital importance of a scalable biomanufacturing platform in advancing therapies that comply with both national and international regulatory standards. With China's rigorous regulations in place, the partnership with RoosterBio equips MineBio to meet the demanding needs of their clients, ensuring compliance while minimizing overall operational costs.

From immediate order acceptance through this partnership, the collaboration aims to drive clinical success for companies involved in cell and gene therapy within China. With increased demand for high-quality and compliant manufacturing materials, this alliance will streamline workflows for ongoing and future projects in China’s dynamic biopharmaceuticals market.

Conclusion

As RoosterBio and MineBio embark on this important partnership, the impact of their collaboration stands to empower innovation within China’s advanced therapies, allowing developers to make faster strides from lab research to clinical applications. By marrying expertise in scalable bioprocessing with a robust client network, the duo is well-positioned to foster growth in the regenerative medicine sector and enhance patient access to transformative therapies.

For more information about RoosterBio's product offerings available in China or to contact MineBio for specific needs, please visit RoosterBio or reach out at [email protected].